Avience Biomedicals IPO is a book-built issue aggregating ₹30.24 crore, comprising entirely a fresh issue of 14.54 lakh equity shares. The public offering will open for subscription on June 18, 2026, and close on June 22, 2026. The basis of allotment is expected to be finalized on June 23, 2026, while the shares are proposed to be listed on the NSE SME platform on June 25, 2026, subject to completion of the process.
The IPO is priced in the range of ₹196 to ₹208 per share. Investors can apply in lots of 600 shares, with retail investors required to bid for a minimum of 1,200 shares, translating into an investment of ₹2,49,600 at the upper price band. For HNI investors, the minimum application size is 1,800 shares (3 lots), requiring an investment of ₹3,74,400.
The issue is being managed by Fintellectual Corporate Advisors Pvt. Ltd., which is acting as the book-running lead manager, while Skyline Financial Services Pvt. Ltd. has been appointed as the registrar to the issue. Asnani Stock Broker Pvt. Ltd. will serve as the market maker for the IPO.
Industry Outlook
- Avience Biomedicals operates in the healthcare devices and equipment sector, with a focus on In Vitro Diagnostic (IVD) products and biotechnology solutions.
- The Indian diagnostics and medical devices industry is experiencing strong growth, supported by increasing healthcare awareness, higher demand for diagnostic testing, and the expansion of hospitals and laboratory networks.
- Rising life expectancy and a growing emphasis on preventive healthcare are boosting demand for rapid test kits, molecular diagnostics, hematology analysers, and other diagnostic products.
- Government initiatives such as the Production Linked Incentive (PLI) scheme and the development of dedicated medical device parks are encouraging domestic manufacturing and reducing import dependence.
- The company plans to utilize a portion of the IPO proceeds to establish a new manufacturing facility at the YEIDA Medical Device Park in Uttar Pradesh. This expansion is expected to enhance production capabilities, improve cost efficiency, and support future export opportunities.
Avience Biomedicals IPO Objectives
The company intends to utilise the net proceeds from the IPO for the following purposes:
- Establishment of a new manufacturing facility: Approximately ₹15.96 crore will be used to partly finance the capital expenditure for setting up a new manufacturing unit at Industrial Plot No. 70, Sector 28, Medical Device Park under the Yamuna Expressway Industrial Development Authority (YEIDA) in Gautam Buddha Nagar, Uttar Pradesh.
- Working capital requirements: Around ₹8.25 crore will be allocated towards meeting the company's working capital requirements and supporting its day-to-day operations and future growth plans.
- General corporate purposes: A portion of the proceeds will be utilised for general corporate purposes.
- Total utilisation: The company plans to utilise ₹24.21 crore of the net proceeds towards these objectives.
About Avience Biomedicals Limited
Founded in June 2024, Avience Biomedicals Limited is an ISO-certified healthcare company engaged in the manufacturing, supply, and export of molecular diagnostic solutions for the biotechnology, genomics, and in-vitro diagnostics (IVD) sectors. The company has broadened its portfolio beyond rapid diagnostic test kits to include a wide range of medical and diagnostic products such as serology solutions, biochemistry analysers, molecular diagnostic kits, haematology analysers, oxygen concentrators, and viral transport media. Its offerings serve pathology laboratories, microbiology laboratories, hospitals, and research institutions across India and international markets.
Alongside its manufacturing operations, Avience Biomedicals is also involved in the distribution and trading of medical equipment. The company's manufacturing facility is located in Noida, Uttar Pradesh. As of 31 January 2026, it employed 75 permanent staff and 33 contractual employees.
The company’s strengths include its experienced management team, diversified diagnostic product portfolio, and an extensive distribution network across India with a growing presence in overseas markets. Avience focuses on providing cost-effective healthcare solutions while maintaining stringent quality standards through adherence to ISO certifications and other regulatory requirements. Its broad product range and commitment to quality position it well to cater to the evolving needs of the healthcare diagnostics industry.
How To Check the Allotment Status of the Avience Biomedicals IPO?
Steps to check IPO allotment status on Angel One’s app:
- Log in to the Angel One app.
- Go to the IPO Section and then to IPO Orders.
- Select the individual IPO that you had applied for and check the allotment status.
- Angel One will notify you of your IPO allotment status via push notification and email.
How To Apply for Avience Biomedicals IPO Online?
- Login to Your Angel One Account: Open the Angel One app or website and log in with your credentials.
- Locate the IPO Section: Navigate to the 'IPO' section on the platform.
- Select IPO: Find and select the Avience Biomedicals IPO from the list of open IPOs.
- Enter the Lot Size: Specify the number of lots you want to bid for.
- Submit Your UPI ID: Enter your UPI ID to link your payment method and submit your application.
- Approve Funds: Once you receive the bid request on your UPI app, approve it by entering your UPI PIN.
Contact Details of Avience Biomedicals IPO
Registered Office:Avience Biomedicals Ltd. Address- C-11, Block-C, Community Centre, Janakpuri A-3, Delhi, New Delhi, 110058
Phone:1800-12-04-636
E‑mail:info@avienbio.com
Avience Biomedicals IPO Reservation
| Investor Category | Shares Offered | % of Net Issue | % of Total Issue |
| QIB Shares Offered | 6,83,400 | 49.83% | 47.01% |
| └─ Anchor Investor Shares Offered | 4,09,800 | – | 28.19% |
| └─ QIB (Excluding Anchor) Shares Offered | 2,73,600 | – | 18.82% |
| NII (HNI) Shares Offered | 2,07,000 | 15.09% | 14.24% |
| └─ bNII (> ₹10 lakh) | 1,38,000 | – | 9.49% |
| └─ sNII (< ₹10 lakh) | 69,000 | – | 4.75% |
| Retail Individual Investors (RII) | 4,81,200 | 35.08% | 33.10% |
| Market Maker Reservation | 82,200 | – | 5.65% |
| Total Shares Offered | 14,53,800 | 100.00% | 100.00% |
Avience Biomedicals IPO Promoter Holding
The promoters of the company are Mr. Dharam Deo Choudhary, Mr. Ram Nagina Choudhary, Mr. Janardan Pal and Ms. Deepa Choudhary.
| Share Holding Pre-Issue | 87.89% |
| Share Holding Post Issue | 64.59% |
Key Performance Indicators for Avience Biomedicals IPO
| KPI | Jan 31 2026 | Mar 31 2025 |
| ROE (%) | 22.38% | 50.14% |
| ROCE (%) | 16.99% | 24.84% |
| Debt-to-Equity Ratio | 0.94 | 0.97 |
| RoNW (%) | 22.38% | 49.89% |
| PAT Margin (%) | – | 15.86% |
| EBITDA Margin (%) | 24.70% | 25.22% |
| Price-to-Book Value (x) | 2.94 | 3.68 |
Avience Biomedicals IPO Prospectus
Avience Biomedicals IPO Registrar and Lead Managers
Avience Biomedicals IPO Lead Managers
- Fintellectual Corporate Advisors Pvt.Ltd
Registrar for Avience Biomedicals IPO
Skyline Financial Services Pvt.Ltd.
- Contact Number: 02228511022
- Email Address: ipo@skylinerta.com
Financial Performance of Avience Biomedicals Limited
| Particulars | Jan 31 2026 | Mar 31 2025 | Mar 31 2024 |
| Assets | 66.07 | 56.52 | 34.65 |
| Total Income | 41.94 | 45.97 | 24.37 |
| Profit After Tax (PAT) | 5.74 | 7.23 | 2.14 |
| EBITDA | 10.34 | 11.41 | 4.08 |
| Net Worth | 28.52 | 22.78 | 6.21 |
| Reserves & Surplus | 24.49 | 18.75 | 2.93 |
| Total Borrowings | 26.73 | 22.16 | 15.13 |
Strengths and Opportunities of Avience Biomedicals IPO
- The company has demonstrated strong financial growth, with revenue increasing from ₹23.96 crore in FY24 to ₹45.24 crore in FY25, while profit after tax rose from ₹2.14 crore to ₹7.23 crore during the same period.
- It offers a diversified portfolio of diagnostic and healthcare products, including rapid diagnostic test kits, molecular diagnostics, serology products, biochemistry analysers, and haematology analysers.
- The company has obtained several recognised certifications, including ISO 9001, ISO 13485, GMP, and ZED MSME Gold, reflecting its focus on quality and regulatory compliance.
- Avience is among the few domestic manufacturers to receive ICMR validation for sickle cell testing, strengthening its credibility in the diagnostics market.
- Since the IPO consists entirely of a fresh issue, the funds raised will be directed towards business expansion and capacity enhancement rather than providing an exit to existing shareholders.
- A significant portion of the IPO proceeds will be used to establish a new manufacturing facility in the Medical Device Park under YEIDA in Gautam Buddha Nagar, Uttar Pradesh.
- The proposed facility is expected to enhance production capacity, enabling the manufacture of more than 3.6 crore rapid diagnostic tests and 50,000 litres of reagents annually.
Risks and Threats of Avience Biomedicals IPO
- A substantial portion of Avience Biomedicals' revenue is generated through trading activities rather than in-house manufacturing, which could make its profitability more vulnerable to market fluctuations and margin pressures.
- The company has a concentrated customer base, with a significant share of revenue derived from a limited number of clients. The loss of any major customer could adversely affect its financial performance.
- The company has reported negative cash flows in certain periods, which may increase its reliance on external funding to support operations and future growth.
- Avience imports part of its raw materials and medical equipment from China, exposing it to risks such as supply chain disruptions, changes in import duties, foreign exchange fluctuations, and geopolitical uncertainties.
- Dependence on third-party suppliers for certain products and equipment could lead to procurement delays, supply shortages, or increased costs.
- The healthcare diagnostics and medical devices industry operates under stringent regulatory requirements. Any failure to comply with applicable standards and regulations could result in penalties, product recalls, legal disputes, or restrictions on operations.
- The company intends to establish a new manufacturing facility using the IPO proceeds. Any delays in project execution, cost overruns, or operational challenges could impact the expected benefits of the expansion.
